VIDEO: Yutiq shows positive real-world results in chronic noninfectious uveitis at 3 years

ByMichael Singer, MD

ByAnthony DeFino

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, of the University of Texas Health Science Center, discusses 36-month data investigating Yutiq for chronic noninfectious uveitis.

The CALM registry study investigated Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg, Alimera Sciences) in 267 eyes and its impact on uveitis recurrence, OCT visual acuity, visual haze, IOP and safety data.

“This real-world study builds on the controlled clinical trials that show that this is a relatively safe and effective therapy,” he said. “Three years after the implant, there is a substantial reduction in uveitis flares, there is an improved OCT and stable vision, and a relatively safe and consistent IOP profile.”

Published by:

Sources/Disclosures

Collapse

Source:

Singer M. The CALM registry: 36 months data. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Singer reports being a consultant and speaker for Alimera Sciences.

Clinical Trials at the Summit meeting

Read more

VIDEO: Yutiq shows positive real-world results in chronic noninfectious uveitis at 3 years

Related Content